Tag: American Diabetes Association

The American Diabetes Association Marks 85 Years of Advancements in Diabetes Care and Discovery

ARLINGTON, Va., Aug. 5, 2025 /PRNewswire/ -- This month, the American Diabetes Association® (ADA) celebrates 85 years of dedicated work toward its vision of...

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

The Inner Circle acknowledges, Shiva Pejman-Aryan, APRN. FNP-C. PMHNP-BC as a Pinnacle Lifetime Member

AUSTIN, Texas, July 1, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Shiva Pejman-Aryan, APRN. FNP-C. PMHNP-BC and DNP (Candidate) is acknowledged as...

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and...

Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic^® (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression

Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes

Oral formulation demonstrates comparable cardiovascular benefits to injectable GLP-1s CHICAGO, June 22, 2025 /PRNewswire/ -- A recent study found that oral semaglutide offers meaningful cardiovascular benefits...

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans...

Once-Weekly Insulin Efsitora Achieves Comparable A1C Reduction to Daily Insulin Therapy

Once-weekly insulin helped patients achieve an average A1C of 6.92% in QWINT-1 trial Results support once-weekly insulin as effective alternative to daily treatment CHICAGO, June 22,...

Inhaled Insulin Shown as a Safe and Effective Replacement for Standard-of-Care in Children with Type 1 Diabetes

Findings Highlight Potential for Novel Approach to Insulin Delivery in Pediatric Population CHICAGO, June 22, 2025 /PRNewswire/ -- Today, a new study demonstrates inhaled insulin...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsAmerican Diabetes Association

Pennsylvania Public Utility Commission approves new distribution rates for PPL Electric Utilities prioritizing reliability, customer protections and long-term affordability

CCC, Evacusled supply patented Canadian emergency evacuation equipment to U.S. military

Centre for Neuro Skills’ Chris Persel Receives First-Ever Enduring Contributions Award

Tag: American Diabetes Association

The American Diabetes Association Marks 85 Years of Advancements in Diabetes Care and Discovery

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

The Inner Circle acknowledges, Shiva Pejman-Aryan, APRN. FNP-C. PMHNP-BC as a Pinnacle Lifetime Member

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and...

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Once-Weekly Insulin Efsitora Achieves Comparable A1C Reduction to Daily Insulin Therapy

Inhaled Insulin Shown as a Safe and Effective Replacement for Standard-of-Care in Children with Type 1 Diabetes

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us